Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Schaeffler AG: CDP score – Schaeffler achieves “A” for performance on climate change and water security: https://upload.wikimedia.org/wikipedia/commons/thumb/7/72/Schaeffler_logo.svg/640px-Schaeffler_logo.svg.png
EQS-News: Schaeffler AG: CDP score – Schaeffler achieves “A” for performance on climate change and water security
EQS-News: Schaeffler AG: CDP score – Schaeffler achieves “A” for performance on climate change and water security
eqs_en 
0 13.12.22
EQS-Adhoc: Deutsche Lufthansa AG: Lufthansa Group raises earnings forecast for 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23600/375px-Lufthansa-Logo.svg.png
EQS-Adhoc: Deutsche Lufthansa AG: Lufthansa Group raises earnings forecast for 2022
EQS-Adhoc: Deutsche Lufthansa AG: Lufthansa Group raises earnings forecast for 2022
eqs_en 
0 13.12.22
EQS-News: HELLA GmbH & Co. KGaA: HELLA completes exit from HBPO: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23717/225px-HELLA_Logo_3D_Background_4C_300dpi.jpg
EQS-News: HELLA GmbH & Co. KGaA: HELLA completes exit from HBPO
EQS-News: HELLA GmbH & Co. KGaA: HELLA completes exit from HBPO
eqs_en 
0 12.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 12.12.22
EQS-News: GRENKE achieves top ranking in DVFA’s Corporate Governance Scorecard : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24105/Grenke_Logo.jpg
EQS-News: GRENKE achieves top ranking in DVFA’s Corporate Governance Scorecard
EQS-News: GRENKE achieves top ranking in DVFA’s Corporate Governance Scorecard
eqs_en 
0 12.12.22
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 
eqs_en 
0 11.12.22
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 
eqs_en 
0 11.12.22
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
eqs_en 
0 10.12.22
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
eqs_en 
0 10.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 09.12.22
CTS EVENTIM is the exclusive ticketing provider of the World Athletics Championships Budapest 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23704/EVE_Logo.svg.png
CTS EVENTIM is the exclusive ticketing provider of the World Athletics Championships Budapest 2023
CTS EVENTIM is the exclusive ticketing provider of the World Athletics Championships Budapest 2023
eqs_en 
0 09.12.22
EQS-News: Stabilus SE confirms preliminary figures for FY2022 and proposes dividend of €1.75 per share: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24125/375px-Stabilus_logo.svg.png
EQS-News: Stabilus SE confirms preliminary figures for FY2022 and proposes dividend of €1.75 per share
EQS-News: Stabilus SE confirms preliminary figures for FY2022 and proposes dividend of €1.75 per share
eqs_en 
0 09.12.22
Monro Waives Battery Installation Charges along with Other Strategic Initiatives: https://mms.businesswire.com/media/20221208005915/en/1659962/5/Battery_Installation.jpg
Monro Waives Battery Installation Charges along with Other Strategic Initiatives


Monro, Inc. (Nasdaq: MNRO) recently implemented a series of initiatives designed to help customers prepare for winter driving. These efforts are part of a forward-looking strategic plan to position

BusinessWire_EN 
0 08.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 08.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 07.12.22
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
eqs_en 
0 06.12.22
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
eqs_en 
0 06.12.22
CTS Eventim AG & Co. KGaA: Holger Hohrein to join CTS EVENTIM as Chief Financial Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23704/EVE_Logo.svg.png
CTS Eventim AG & Co. KGaA: Holger Hohrein to join CTS EVENTIM as Chief Financial Officer
CTS Eventim AG & Co. KGaA: Holger Hohrein to join CTS EVENTIM as Chief Financial Officer
eqs_en 
0 06.12.22
Semtech’s LoRa® Devices Optimize Building Management Systems in U.S.: https://mms.businesswire.com/media/20221206005334/en/1655900/5/lora-talkpoop-nordic-propeye-pr-press.jpg
Semtech’s LoRa® Devices Optimize Building Management Systems in U.S.


Semtech Corporation (Nasdaq: SMTC), a leading global supplier of high performance analog and mixed-signal semiconductors and advanced algorithms, announced that Sweden-based Nordic Propeye, an

BusinessWire_EN 
0 06.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 06.12.22
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
eqs_en 
0 06.12.22
EQS-Adhoc: Talanx Aktiengesellschaft: New dividend policy: Dividend for financial year 2022 to be increased to EUR 2.00: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23745/Talanx.svg.png
EQS-Adhoc: Talanx Aktiengesellschaft: New dividend policy: Dividend for financial year 2022 to be increased to EUR 2.00
EQS-Adhoc: Talanx Aktiengesellschaft: New dividend policy: Dividend for financial year 2022 to be increased to EUR 2.00
eqs_en 
0 05.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 05.12.22
EQS-News: Aurubis AG: Focus on recycling: Aurubis makes the final round of the 15th German Sustainability Award: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23699/Aurubis-Logo.svg.png
EQS-News: Aurubis AG: Focus on recycling: Aurubis makes the final round of the 15th German Sustainability Award
EQS-News: Aurubis AG: Focus on recycling: Aurubis makes the final round of the 15th German Sustainability Award
eqs_en 
0 03.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 02.12.22